Luca Degli Esposti

Dr. Luca Degli Esposti

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2011 in ClinicoEconomics and Outcomes Research
Verified
Journal Article
Open access
LELuca Degli Esposti
Luca Degli Esposti
SSStefania Saragoni
Stefania Saragoni
SBSIlvia Benemei
SIlvia Benemei
PBPaolo Batacchi
Paolo Batacchi
PGPierangelo Geppetti
Pierangelo Geppetti
EEEzio Degli Esposti
Ezio Degli Esposti
Peer reviewed article authored by (Luca Degli Esposti, Stefania Saragoni, Silvia Benemei, et al). Read article or submit your manuscript for publishing.

1 August 2002 in Clinical Therapeutics
Verified
Journal Article
Closed access
LELuca Degli Esposti
Luca Degli Esposti
EEEzio Degli Esposti
Ezio Degli Esposti
GVGiorgia Valpiani
Giorgia Valpiani
Mirko Di MartinoMirko Di Martino
Mirko Di Martino
SSStefania Saragoni
Stefania Saragoni
ASAlessandra Sturani
Alessandra Sturani

1 March 2021 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
EGElisa Giacomini
Elisa Giacomini
VPValentina Perrone
Valentina Perrone
DADavide Alessandrini
Davide Alessandrini
DPDaniela Paoli
Daniela Paoli
CNCarmela Nappi
Carmela Nappi
LELuca Degli Esposti
Luca Degli Esposti
The 20th century witnessed the dawn of the antibiotic revolution and is now facing the rising phenomenon of antibiotic resistance. In this narrative review, we aim to describe antibiotic resistance in clinical practice settings through population-based studies from different countries reporting the role of misuse of antibiotics in the development of resistance and the clinical and economic burden associated. The misuse of antibiotics was documented in the wide population as well as in hospitals and care facilities. It was mainly reported as over-use and inappropriate prescribing. Improper dosage regimens and longer treatment duration were regarded as pivotal factors related to antibiotic resistance; the emerging strategy of “antibiotic-de-escalation” could be the key to overcome these issues. The investigation of the self-medication attitude revealed widespread antibiotic use without following medical instructions or medical consultation. Moreover, several studies established the association of antibiotic resistance with increased risk of longer hospitalizations and mortality, highlighting the heavy clinical and economic burden of this phenomenon. In this narrative review, the widespread inappropriate use of antibiotics emerged as one of the main causes of antibiotic resistance, which negative outcomes call for the development of antibiotic stewardship programs and global surveillance networks.

1 February 2004 in The Journal of Clinical Hypertension
Verified
Journal Article
Open access
PDF file
LELuca Degli Esposti
Luca Degli Esposti
MMMirko Di Martino
Mirko Di Martino
SSStefania Saragoni
Stefania Saragoni
ASAndrea Sgreccia
Andrea Sgreccia
ACAlessandro Capone
Alessandro Capone
EEEzio Degli Esposti
Ezio Degli Esposti
The objective of the research was to perform a clinical practice‐based analysis of how long patients remain on various antihypertensive drugs. An administrative database listing of patient baseline characteristics, drug prescriptions, and hospital admissions was used. All new users of antihypertensive drugs, ≥20 years of age, receiving a first prescription for diuretics, β blockers, calcium channel blockers, angiotensin‐converting enzyme inhibitors, or angiotensin II receptor antagonists between January 1, 2000, and December 31, 2000, were included and observed for 365 days. Persistence was defined as a duration of therapy >273 days. A total of 14,062 patients were included in the study, 39.7% of whom remained on treatment (persistent patients). Persistent patients were more likely to be older, taking other drugs for concurrent disorders, hospitalized for cardiovascular diseases, and initially prescribed angiotensin II receptor antagonists. Persistent patients accounted for 80.6% of the overall cost for antihypertensive drugs. Factors associated with drug cost were age, pattern of persistence, number of prescribed classes, and specific medication at enrollment. Measuring persistence with treatment is needed to evaluate the appropriateness and the cost‐effectiveness of drug use.

4 December 2018 in Endocrine
Verified
Journal Article
Closed access
PDF file
OGon the behalf of the Study group
on the behalf of the Study group
LELuca Degli Esposti
Luca Degli Esposti
AGAnna Girardi
Anna Girardi
SSStefania Saragoni
Stefania Saragoni
SSStefania Sella
Stefania Sella
SGSandro Giannini
Sandro Giannini

1 May 2013 in ClinicoEconomics and Outcomes Research
Verified
Journal Article
Open access
PDF file
LELuca Degli Esposti
Luca Degli Esposti
DEDegli Esposti
Degli Esposti
SBStefano Buda
Stefano Buda
SSStefania Saragoni
Stefania Saragoni
ASAlessandra Sturani
Alessandra Sturani
Background: Diabetes is one of the most prevalent chronic diseases, and its prevalence is predicted to increase in the next two decades. Diabetes imposes a staggering financial burden on the health care system, so information about the costs and experiences of collecting and reporting quality measures of data is vital for practices deciding whether to adopt quality improvements or monitor existing initiatives. The aim of this study was to quantify the association between health care costs and level of glycemic control in patients with type 2 diabetes using clinical and administrative databases. Methods: A retrospective analysis using a large administrative database and a clinical registry containing laboratory results was performed. Patients were subdivided according to their glycated hemoglobin level. Multivariate analyses were used to control for differences in potential confounding factors, including age, gender, Charlson comorbidity index, presence of dyslipidemia, hypertension, or cardiovascular disease, and degree of adherence with antidiabetic drugs among the study groups. Results: Of the total population of 700,000 subjects, 31,022 were identified as being diabetic (4.4% of the entire population). Of these, 21,586 met the study inclusion criteria. In total, 31.5% of patients had very poor glycemic control and 25.7% had excellent control. Over 2 years, the mean diabetes-related cost per person was: €1291.56 in patients with excellent control; €1545.99 in those with good control; €1584.07 in those with fair control; €1839.42 in those with poor control; and €1894.80 in those with very poor control. After adjustment, compared with the group having excellent control, the estimated excess cost per person associated with the groups with good control, fair control, poor control, and very poor control was €219.28, €264.65, €513.18, and €564.79, respectively. Conclusion: Many patients showed suboptimal glycemic control. Lower levels of glycated hemoglobin were associated with lower diabetes-related health care costs. Integration of administrative databases and a laboratory database appears to be suitable for showing that appropriate management of diabetes can help to achieve better resource allocation.